Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471614 · ClinicalTrials.gov registry record · Phase 2
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00471614 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 3 participants.
The verdict
NCT00471614, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether uridine supplementation will improve insulin sensitivity and overall carbohydrate metabolism in HIV-positive subjects who are currently undergoing treatment with antiretroviral regimens containing stavudine or zidovudine and who have evidence of impaired mitochondrial function and insulin resistance.
Interventions
- DRUG NucleomaxX (contains uridine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471614
The ClinicalTrials.gov registry entry for NCT00471614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NucleomaxX (contains uridine) is the first listed.
NCT00471614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471614 about?
NCT00471614 is a clinical study titled "Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine". The purpose of this study is to determine whether uridine supplementation will improve insulin sensitivity and overall carbohydrate metabolism in HIV-positive subjects who are currently undergoing treatment with antiretroviral regimens containing stavudine or zidovudine and who have evidence of impa...
What is the current status of trial NCT00471614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-04. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00471614?
The interventions under investigation include: NucleomaxX (contains uridine) (DRUG).
Who is sponsoring clinical trial NCT00471614?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.